Janine LaSalle is associate director of genomics at the University of California, Davis, Genome Center.
Janine LaSalle
Associate director of genomics
Genome Center, University of California, Davis
From this contributor
Chemical tags reveal interplay of genes, environment in autism
The landscape of chemical modifications on the DNA of people with autism could reveal clues to the condition and lead to treatments.
Chemical tags reveal interplay of genes, environment in autism
By
Janine LaSalle
20 June 2017 | 5 min read
Genes and environment are two-way street in autism risk
Genes and the environment each influence the role of the other in determining the risk of developing autism. Genetics can determine how susceptible one is to the environment, and environmental factors can influence gene expression and introduce mutations, says immunologist Janine LaSalle.
Genes and environment are two-way street in autism risk
By
Janine LaSalle
21 August 2012 | 6 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read